9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: We aimed to estimate the usefulness of a disease specific health status measure, the St George's Respiratory Questionnaire (SGRQ), to predict outcomes in patients with chronic obstructive pulmonary disease (COPD). Methods: Individual patient-data of 12043 patients from long-term randomized clinical trials (2-4 years' duration) in the COPD Biomarkers Qualification Consortium database were analyzed. The adverse COPD outcomes were: exacerbations of COPD, hospital admissions due to exacerbation and all-cause mortality. Cox proportional hazards regression was used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for quartiles of SGRQ scores at baseline and time to first event, and time from first to second event, where appropriate. Results: The risk of adverse COPD outcomes increased with each increasing quartile of SGRQ score for all time to first event analyses. When comparing the lowest versus the highest quartile, the event risk (HRs [95% CIs]) increased by 40% for exacerbations (1.40 [1.29, 1.51]); 2-fold for hospital admissions (2.01 [1.78, 2.28]) and more than 2-fold for all-cause mortality (2.30 [1.91, 2.78]). For second event analyses in a subset of eligible patients, these trends persisted albeit with reduced risk estimates for exacerbations. Conclusions: Among patients with COPD, health status measured by a SGRQ score predicted exacerbations of COPD, hospital admissions due to exacerbations and their recurrence and death after adjustment. These data support the rationale for a health status measure use as a drug development tool and suggest that a health status measure may also have a role in risk assessment for COPD patients in routine medical care.

          Related collections

          Author and article information

          Journal
          Chronic Obstr Pulm Dis
          Chronic obstructive pulmonary diseases (Miami, Fla.)
          COPD Foundation
          2372-952X
          2372-952X
          Mar 28 2017
          : 4
          : 2
          Affiliations
          [1 ] Research and Development, GlaxoSmithKline, Uxbridge, United Kingdom.
          [2 ] Evidera, Bethesda, Maryland.
          [3 ] Research and Development, AstraZeneca, Gothenburg, Sweden.
          [4 ] Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.
          [5 ] Division of Pulmonary, Critical Care, Sleep and Allergy, Nebraska Medical Center, Omaha.
          [6 ] AstraZeneca, Cambridge, United Kingdom.
          [7 ] Respiratory Therapy Area Unit, Research and Development, GlaxoSmithKline, King of Prussia, Pennsylvania.
          [8 ] COPD Foundation, Washington, D.C.
          [9 ] Institute of Infection and Immunity, St George's University of London, United Kingdom.
          Article
          10.15326/jcopdf.4.2.2017.0131
          5559113
          28848923
          d3429866-c08d-4ad7-bc68-12e08a7f0633
          History

          CBQC,COPD Biomarkers Qualification Consortium,COPD outcomes,SGRQ,St George’s Respiratory Questionnaire,predictive validity

          Comments

          Comment on this article